Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

Progress in Cardiovascular Diseases

Volumn 49, Issue 2, 2006, Pages 123-151

  Sherrid, Mark V ^a  

^a Echocardiography Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

ARTICLE; BACTERIAL ENDOCARDITIS; BLURRED VISION; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; DEFIBRILLATOR; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FAMILY ASSESSMENT; FAMILY HEALTH; HEART BLOCK; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; PATHOPHYSIOLOGY; RISK FACTOR; SUDDEN DEATH; XEROSTOMIA;

CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; ELECTRIC COUNTERSHOCK; HUMANS; PROGNOSIS; STROKE VOLUME;

EID: 33749840303     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.08.001     Document Type: Article

References (177)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 20 (1958) 1-18
2. Seidman J.G., and Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104 (2001) 557-567
3. Mogensen J., Bahl A., and McKenna W.J. Hypertrophic cardiomyopathy-the clinical challenge of managing a hereditary heart condition. Eur. Heart J. 24 (2003) 496-498
4. Watkins H., Rosenzweig A., Hwang D.S., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326 (1992) 1108-1114
5. Van Driest S.L., Ommen S.R., Tajik A.J., et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin. Proc. 80 (2005) 739-744
6. Binder J., Ommen S.R., Gersh B.J., et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin. Proc. 4 (2006) 459-467
7. Lever H.M., Karam R.F., Currie P.J., et al. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 79 (1989) 580-589
8. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355 (2000) 58-60
9. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J. Am. Coll. Cardiol. 42 (2003) 1687-1713
10. Maron B.J., and Epstein S.E. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am. J. Cardiol. 43 (1979) 1242-1244
11. Wigle E.D., Sasson Z., Henderson M.A., et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog. Cardiovasc. Dis. 28 (1985) 1-83
12. Wigle E.D. Hypertrophic cardiomyopathy: a 1987 viewpoint. Circulation 75 (1987) 311-322
13. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 287 (2002) 1308-1320
14. Ommen S.R., and Nishimura R.A. Hypertrophic cardiomyopathy. Curr. Probl. Cardiol. 29 (2004) 239-291
15. Eriksson M.J., Sonnenberg B., Woo A., et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 39 (2002) 638-645
16. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 (2005) 855-861
17. Maron B.J., Wolfson J.K., and Roberts W.C. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am. J. Cardiol. 70 (1992) 785-790
18. Maron B.J., Anan T.J., and Roberts W.C. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 63 (1981) 882-894
19. Varnava A.M., Elliott P.M., Baboonian C., et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 104 (2001) 1380-1384
20. Shirani J., Pick R., Roberts W.C., et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 35 (2000) 36-44
21. St John Sutton M.G., Lie J.T., Anderson K.R., et al. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br. Heart J. 44 (1980) 433-443
22. Tanaka M., Fujiwara H., Onodera T., et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br. Heart J. 55 (1986) 575-581
23. Factor S.M., Butany J., Sole M.J., et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 17 (1991) 1343-1351
24. Nihoyannopoulos P., Karatasakis G., Frenneaux M., et al. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J. Am. Coll. Cardiol. 19 (1992) 536-540
25. Nagueh S.F., Lakkis N.M., Middleton K.J., et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 99 (1999) 344-347
26. Varnava A.M., Elliott P.M., Mahon N., et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am. J. Cardiol. 88 (2001) 275-279
27. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 8 (1986) 545-557
28. Sherrid M.V., Mahenthiran J., Casteneda V., et al. Comparison of diastolic septal perforator flow velocities in hypertrophic cardiomyopathy versus hypertensive left ventricular hypertrophy. Am. J. Cardiol. 97 (2006) 106-112
29. Maron B.J., Epstein S.E., and Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am. J. Cardiol. 43 (1979) 1086-1102
30. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348 (2003) 295-303
31. Sherrid M.V., Chu C.K., Delia E., et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 22 (1993) 816-825
32. Sherrid M.V., Gunsburg D.Z., Moldenhauer S., et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 36 (2000) 1344-1354
33. Shah P.M., Gramiak R., and Kramer D.H. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 40 (1969) 3-11
34. Henry W.L., Clark C.E., Griffith J.M., et al. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am. J. Cardiol. 35 (1975) 337-345
35. Schwammenthal E., and Levine R.A. Dynamic subaortic obstruction: a disease of the mitral valve suitable for surgical repair?. J. Am. Coll. Cardiol. 28 (1996) 203-206
36. Murgo J.P. Does outflow obstruction exist in hypertrophic cardiomyopathy?. N. Engl. J. Med. 307 (1982) 1008-1009
37. Criley J.M., and Siegel R.J. Has 'obstruction' hindered our understanding of hypertrophic cardiomyopathy?. Circulation 72 (1985) 1148-1154
38. Sherrid M.V., Gunsburg D.Z., and Pearle G. Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy-the lobster claw abnormality. J. Am. Soc. Echocardiogr. 10 (1997) 707-712
39. Conklin H.M., Huang X., Davies C.H., et al. Biphasic left ventricular outflow and its mechanism in hypertrophic obstructive cardiomyopathy. J. Am. Soc. Echocardiogr. 17 (2004) 375-383
40. Barac I., Pilchik R., Shteerman E., et al. Midsystolic drop in left ventricular ejection velocity in hypertrophic cardiomyopathy is caused by premature termination and dyssynchrony of longitudinal contraction. Doppler flow and tissue velocity study of the "lobster claw abnormality" (abstract). Circulation 110 Suppl III (2004) 746
41. Klues H.G., Roberts W.C., and Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 84 (1991) 1188-1197
42. Falicov R.E., Resnekov L., Bharati S., et al. Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. Am. J. Cardiol. 37 (1976) 432-437
43. Nakamura T., Matsubara K., Furukawa K., et al. Diastolic paradoxic jet flow in patients with hypertrophic cardiomyopathy: evidence of concealed apical asynergy with cavity obliteration. J. Am. Coll. Cardiol. 19 (1992) 516-524
44. Sasson Z., Yock P.G., Hatle L.K., et al. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 11 (1988) 752-756
45. Marwick T.H., Nakatani S., Haluska B., et al. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. Am. J. Cardiol. 75 (1995) 805-809
46. Klues H.G., Maron B.J., Dollar A.L., et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 85 (1992) 1651-1660
47. Cape E.G., Simons D., Jimoh A., et al. Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies. J. Am. Coll. Cardiol. 13 (1989) 1438-1448
48. Jiang L., Levine R.A., King M.E., et al. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am. Heart J. 113 (1987) 633-644
49. Shah P.M., Taylor R.D., and Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. Am. J. Cardiol. 48 (1981) 258-262
50. Levine R.A., Vlahakes G.J., Lefebvre X., et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 91 (1995) 1189-1195
51. Lefebvre X.P., Yoganathan A.P., and Levine R.A. Insights from in-vitro flow visualization into the mechanism of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy under steady flow conditions. J. Biomech. Eng. 114 (1992) 406-413
52. Vogel S. Life in moving fluids. The physical biology of flow (1994), Princeton University Press, Princeton, NJ 81-155
53. Spirito P., and Maron B.J. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. Am. J. Cardiol. 54 (1984) 1039-1046
54. Maron B.J., Harding A.M., Spirito P., et al. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation 68 (1983) 282-293
55. Sherrid M.V., Chaudhry F.A., and Swistel D.G. Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann. Thorac. Surg. 75 (2003) 620-632
56. Roberts C.S., McIntosh C.L., Brown Jr. P.S., et al. Reoperation for persistent outflow obstruction in hypertrophic cardiomyopathy. Ann. Thorac. Surg. 51 (1991) 455-460
57. Messmer B.J. Extended myectomy for hypertrophic obstructive cardiomyopathy. Ann. Thorac. Surg. 58 (1994) 575-577
58. Schoendube F.A., Klues H.G., Reith S., et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92 (1995) II122-II127
59. Nakatani S., Schwammenthal E., Lever H.M., et al. New insights into the reduction of mitral valve systolic anterior motion after ventricular septal myectomy in hypertrophic obstructive cardiomyopathy. Am. Heart J. 131 (1996) 294-300
60. Grigg L.E., Wigle E.D., Williams W.G., et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J. Am. Coll. Cardiol. 20 (1992) 42-52
61. Balaram S.K., Sherrid M.V., and Derose Jr. J.J. Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair. Ann. Thorac. Surg. 80 (2005) 217-223
62. McIntosh C.L., Maron B.J., and Cannon III R.O. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 86 (1992) II60-II67
63. Spirito P., Rapezzi C., Bellone P., et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 99 (1999) 2132-2137
64. Sorajja P., Ommen S.R., Nishimura R.A., et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 108 (2003) 2342-2348
65. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 342 (2000) 1778-1785
66. Elliott P.M., Gimeno J., Blanes R., et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357 (2001) 420-424
67. Maron B.J., Shen W.K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342 (2000) 365-373
68. Watkins H., McKenna W.J., Thierfelder L., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332 (1995) 1058-1064
69. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102 (2000) 858-864
70. Maron B.J., Roberts W.C., Edwards J.E., et al. Sudden death in patients with hypertrophic cardiomyopathy: characterization of 26 patients with functional limitation. Am. J. Cardiol. 41 (1978) 803-810
71. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J. Am. Coll. Cardiol. 36 (2000) 2212-2218
72. Maron B.J., Roberts W.C., and Epstein S.E. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 65 (1982) 1388-1394
73. Maron B.J., Casey S.A., Poliac L.C., et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281 (1999) 650-655
74. McKenna W.J., Franklin R.C., Nihoyannopoulos P., et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 11 (1988) 147-153
75. McKenna W., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. 47 (1981) 532-538
76. Maron B.J., Mathenge R., Casey S.A., et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J. Am. Coll. Cardiol. 33 (1999) 1590-1595
77. Cecchi F., Olivotto I., Montereggi A., et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J. Am. Coll. Cardiol. 26 (1995) 1529-1536
78. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revised in a large non-referral-based patient population. Circulation 102 (2000) 858-864
79. Maron B.J., and Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am. J. Cardiol. 72 (1993) 970-972
80. Fay W.P., Taliercio C.P., Ilstrup D.M., et al. Natural history of hypertrophic cardiomyopathy in the elderly. J. Am. Coll. Cardiol. 16 (1990) 821-826
81. Elliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 33 (1999) 1596-1601
82. Maron B.J., Lipson L.C., Roberts W.C., et al. "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am. J. Cardiol. 41 (1978) 1133-1140
83. Monserrat L., Elliott P.M., Gimeno J.R., et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 42 (2003) 873-879
84. Sadoul N., Prasad K., Elliott P.M., et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96 (1997) 2987-2991
85. Olivotto I., Maron B.J., Montereggi A., et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 33 (1999) 2044-2051
86. Ciampi Q., Betocchi S., Lombardi R., et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 40 (2002) 278-284
87. Cecchi F., Olivotto I., Montereggi A., et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 79 (1998) 331-336
88. Van Driest S.L., Ellsworth E.G., Ommen S.R., et al. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation 108 (2003) 445-451
89. Mogensen J., Murphy R.T., Kubo T., et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004) 2315-2325
90. Ackerman M.J., VanDriest S.L., Ommen S.R., et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J. Am. Coll. Cardiol. 39 (2002) 2042-2048
91. Van Driest S.L., Ackerman M.J., Ommen S.R., et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106 (2002) 3085-3090
92. Marian A.J., Yu Q.T., Workman R., et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342 (1993) 1085-1086
93. Lechin M., Quinones M.A., Omran A., et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 92 (1995) 1808-1812
94. Saad E.B., Saliba W.I., Schweikert R.A., et al. Nonthoracotomy implantable defibrillator lead extraction: results and comparison with extraction of pacemaker leads. Pacing Clin. Electrophysiol. 26 (2003) 1944-1950
95. Maron B.J., Shirani J., Poliac L.C., et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 276 (1996) 199-204
96. Maron B.J., Isner J.M., and McKenna W.J. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J. Am. Coll. Cardiol. 24 (1994) 880-885
97. Maron B.J., Mitten M.J., Quandt E.F., et al. Competitive athletes with cardiovascular disease-the case of Nicholas Knapp. N. Engl. J. Med. 339 (1998) 1632-1635
98. Lele S.S., Thomson H.L., Seo H., et al. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation 92 (1995) 2886-2894
99. Wigle E.D., Rakowski H., Kimball B.P., et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92 (1995) 1680-1692
100. Schwammenthal E., Nakatani S., He S., et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 98 (1998) 856-865
101. Cecchi F., Olivotto I., Gistri R., et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med. 349 (2003) 1027-1035
102. Cannon III R.O., Rosing D.R., Maron B.J., et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 71 (1985) 234-243
103. Krams R., Kofflard M.J., Duncker D.J., et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97 (1998) 230-233
104. Cannon III R.O., Schenke W.H., Maron B.J., et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 10 (1987) 53-62
105. Nienaber C.A., Hiller S., Spielmann R.P., et al. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J. Am. Coll. Cardiol. 15 (1990) 948-955
106. McKenna W., Harris L., and Deanfield J. Syncope in hypertrophic cardiomyopathy. Br. Heart J. 47 (1982) 177-179
107. Frenneaux M.P., Counihan P.J., Caforio A.L., et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82 (1990) 1995-2002
108. Maron B.J., Casey S.A., Hauser R.G., et al. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J. Am. Coll. Cardiol. 42 (2003) 882-888
109. Kass D.A., Wolff M.R., Ting C.T., et al. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann. Intern. Med. 119 (1993) 466-473
110. TenCate F.J., Serruys P.W., Mey S., et al. Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy. Circulation 68 (1983) 1274-1279
111. Sherrid M., and Barac I. Pharmacologic treatment of symptomatic hypertrophic cardiomyopathy. In: Maron B. (Ed). Diagnosis and management of hypertrophic cardiomyopathy (2004), Blackwell-Futura, London 200-219
112. Bonow R.O., Ostrow H.G., Rosing D.R., et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation 68 (1983) 1062-1073
113. Bonow R.O. Effects of calcium-channel blocking agents on left ventricular diastolic function in hypertrophic cardiomyopathy and in coronary artery disease. Am. J. Cardiol. 55 (1985) 172B-178B
114. Bonow R.O., Rosing D.R., Bacharach S.L., et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64 (1981) 787-796
115. Nishimura R.A., Holmes D.R., and Tajik A.J. Failure of calcium channel blockers to improve ventricular relaxation in humans. J. Am. Coll. Cardiol. 21 (1993) 182-188
116. Udelson J.E., Bonow R.O., O'Gara P.T., et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 79 (1989) 1052-1060
117. Gilligan D.M., Chan W.L., Joshi J., et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 21 (1993) 1672-1679
118. Matsubara H., Nakatani S., Nagata S., et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 26 (1995) 768-775
119. Pollick C., Kimball B., Henderson M., et al. Disopyramide in hypertrophic cardiomyopathy: I. Hemodynamic assessment after intravenous administration. Am. J. Cardiol. 62 (1988) 1248-1251
120. Tsybouleva N., Zhang L., Chen S., et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 109 (2004) 1284-1291
121. Senthil V., Chen S.N., Tsybouleva N., et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ. Res. 97 (2005) 285-292
122. Sherrid M.V., Pearle G., and Gunsburg D.Z. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97 (1998) 41-47
123. Flamm M.D., Harrison D.C., and Hancock E.W. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation 38 (1968) 846-858
124. Stenson R.E., Flamm Jr. M.D., Harrison D.C., et al. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am. J. Cardiol. 31 (1973) 763-773
125. Rosing D.R., Condit J.R., Maron B.J., et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am. J. Cardiol. 48 (1981) 545-553
126. Rosing D.R., Kent K.M., Maron B.J., et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: II. Effects on exercise capacity and symptomatic status. Circulation 60 (1979) 1208-1213
127. Sherrid M.V., Barac I., McKenna W.J., et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 45 (2005) 1251-1258
128. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N. Engl. J. Med. 307 (1982) 997-999
129. Sherrid M., Delia E., and Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 62 (1988) 1085-1088
130. Pollick C. Disopyramide in hypertrophic cardiomyopathy: II. Noninvasive assessment after oral administration. Am. J. Cardiol. 62 (1988) 1252-1255
131. Rosing D.R., Idanpaan-Heikkila U., Maron B.J., et al. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am. J. Cardiol. 55 (1985) 185B-195B
132. Rosing D.R., Kent K.M., Borer J.S., et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: I. Hemodynamic effects. Circulation 60 (1979) 1201-1207
133. Epstein S.E., and Rosing D.R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 64 (1981) 437-441
134. Pollick C.G.K., Blaschke T.F., Nelson W.L., et al. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation 66 (1982) 447-453
135. Olivotto I., Maron B.J., and Cecchi F. Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Curr. Cardiol. Rep. 3 (2001) 141-146
136. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104 (2001) 2517-2524
137. Maron B.J., Olivotto I., Bellone P., et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 39 (2002) 301-307
138. Robinson K., Frenneaux M.P., Stockins B., et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. 15 (1990) 1279-1285
139. Herweg B., Polosajian L., Vloka M., et al. Anatomic substrate, procedural results and clinical outcome of ultrasound-guided left atrial-pulmonary vein disconnection for treatment of atrial fibrillation. Am. J. Cardiol. 95 (2005) 871-875
140. Williams W.G., Wigle E.D., Rakowski H., et al. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 76 (1987) V104-V108
141. Maron B.J., Dearani J.A., Ommen S.R., et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004) 2044-2053
142. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 46 (2005) 470-476
143. McCully R.B., Nishimura R.A., Bailey K.R., et al. Hypertrophic obstructive cardiomyopathy: preoperative echocardiographic predictors of outcome after septal myectomy. J. Am. Coll. Cardiol. 27 (1996) 1491-1496
144. McCully R.B., Nishimura R.A., Tajik A.J., et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 94 (1996) 467-471
145. Schulte H.D., Borisov K., Gams E., et al. Management of symptomatic hypertrophic obstructive cardiomyopathy-long-term results after surgical therapy. Thorac. Cardiovasc. Surg. 47 (1999) 213-218
146. Schulte H.D., Bircks W.H., Loesse B., et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years. J. Thorac. Cardiovasc. Surg. 106 (1993) 709-717
147. Schoendube F.A., Klues H.G., Reith S., et al. Surgical correction of hypertrophic obstructive cardiomyopathy with combined myectomy, mobilisation and partial excision of the papillary muscles. Eur. J. Cardiothorac. Surg. 8 (1994) 603-608
148. Heric B., Lytle B.W., Miller D.P., et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J. Thorac. Cardiovasc. Surg. 110 (1995) 195-206 [discussion 206-8]
149. Qin J.X., Shiota T., Lever H.M., et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J. Am. Coll. Cardiol. 38 (2001) 1994-2000
150. Marwick T.H., Stewart W.J., Lever H.M., et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 20 (1992) 1066-1072
151. Ommen S.R., Park S.H., Click R.L., et al. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am. J. Cardiol. 90 (2002) 1022-1024
152. Krajcer Z., Leachman R.D., Cooley D.A., et al. Mitral valve replacement and septal myomectomy in hypertrophic cardiomyopathy. Ten-year follow-up in 80 patients. Circulation 78 (1988) I35-I43
153. Roberts W.C. Operative treatment of hypertrophic obstructive cardiomyopathy. The case against mitral valve replacement. Am. J. Cardiol. 32 (1973) 377-381
154. Seggewiss H., Gleichmann U., Faber L., et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J. Am. Coll. Cardiol. 31 (1998) 252-258
155. Lakkis N.M., Nagueh S.F., Kleiman N.S., et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98 (1998) 1750-1755
156. Nagueh S.F., Lakkis N.M., He Z.X., et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 32 (1998) 225-229
157. Faber L., Seggewiss H., Fassbender D., et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography. Z. Kardiol. 87 (1998) 191-201
158. Faber L., Ziemssen P., and Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J. Am. Soc. Echocardiogr. 13 (2000) 1074-1079
159. Gietzen F.H., Leuner C.J., Obergassel L., et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 106 (2002) 454-459
160. Lakkis N., Plana J.C., Nagueh S., et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am. J. Cardiol. 88 (2001) 583-586
161. Faber L., Seggewiss H., Welge D., et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur. J. Echocardiogr. 5 (2004) 347-355
162. Flores-Ramirez R., Lakkis N.M., Middleton K.J., et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 37 (2001) 208-214
163. Fernandes V.L., Nagueh S.F., Wang W., et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy-the Baylor experience (1996-2002). Clin. Cardiol. 28 (2005) 124-130
164. Nagueh S.F., Ommen S.R., Lakkis N.M., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 38 (2001) 1701-1706
165. Fananapazir L., Epstein N.D., Curiel R.V., et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90 (1994) 2731-2742
166. Maron B.J., Nishimura R.A., McKenna W.J., et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99 (1999) 2927-2933
167. Kappenberger L., Linde C., Daubert C., et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur. Heart J. 18 (1997) 1249-1256
168. Jeanrenaud X., and Kappenberger L. Regional wall motion during pacing for hypertrophic obstructive cardiomyopathy. Pacing Clin. Electrophysiol. 20 (1997) 1673-1681
169. Nishimura R.A., Hayes D.L., Ilstrup D.M., et al. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J. Am. Coll. Cardiol. 27 (1996) 421-430
170. Ommen S.R., Nishimura R.A., Squires R.W., et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J. Am. Coll. Cardiol. 34 (1999) 191-196
171. Gadler F., Linde C., Daubert C., et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing in cardiomyopathy. Eur. Heart J. 20 (1999) 1044-1050
172. Linde C., Gadler F., Kappenberger L., et al. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing in cardiomyopathy. Am. J. Cardiol. 83 (1999) 903-907
173. Nishimura R.A., Trusty J.M., Hayes D.L., et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J. Am. Coll. Cardiol. 29 (1997) 435-441
174. Gadler F., Linde C., and Ryden L. Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 83 (1999) 553-557
175. Topilski I.S.J., Keren G., and Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am. J. Cardiol. 97 (2006) 1769-1775
176. Topol E.J., Traill T.A., and Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. N. Engl. J. Med. 312 (1985) 277-283
177. Spirito P., Maron B.J., Bonow R.O., et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am. J. Cardiol. 60 (1987) 123-129